- Roger J. Howe, PhD, Executive Chairman
- Maynard A. Howe, PhD, Chief Executive Officer and Vice Chairman
- Nikolai I. Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer
- Alex Kharazi, MD, PhD, Vice President of Medical Research
- Eugene Baranov, PhD, Vice President of Global Research
- Derek Howe, BS, Vice President of Operations
- Harris Brotman, PhD, JD, Vice President of Intellectual Property
- David M. McGuigan. Vice President of Marketing
- David A. Howe, MD, MBA, DC, CCN, Vice President &anp; Medical Director
- Alan Vitums, Controller & Director of Finance
- Alexei V. Lukashev, PhD, Director of Laser Stem Cell Division
the past twenty-five years, Dr. Howe founded five successful start-up
ventures in the medical technology and information systems business
sector. In his past role as Chief Executive Officer of his companies,
he worked with venture capital and investment banking firms obtaining
their participation while moving these companies into commercialization.
As the former chairman and CFO of Reliant Technologies he co-lead
the efforts to secure funding and successfully re-lauch the company.
Reliant Technologies is a medical laser company that developed
and launched a revolutionary, FDA-approved medical laser for skin
surgery known as Fraxel. He is the former CEO and current Board
Member of Cardiovascular Systems, a company with an FDA-approved
technology that removes atherosclerotic blockages in peripheral
arteries. With FDA approval, Cardiovascular Systems has now moved
into an aggressive commercialization phase.
CEO and Founder of National Information Systems, Inc. (one of
his start-up ventures), a leading customer and marketing research
company, his company was responsible for conducting extensive
marketing and branding campaigns, marketing assessments, and
trend research in both business-to-business and business-to-consumer
environments for leading Fortune 500 corporations. Metrix Communications,
(another of his ventures), was one of the most successful IBM
Premium Partners that focused on the development of custom applications
for Internet, Manufacturing, and Supply Chain Management. The
company developed sophisticated, award winning integrated systems
primarily for Fortune 100 corporations.
Dr. Howe is an investor in several ventures and serves on the
Board of Directors for several companies including: BioPharma
Scientific, a pioneer in the emerging field of combining nutraceuticals
with proprietary pharmaceutical delivery; Cardiovascular Systems;
Americas Back Medical Clinic which has technology that treats
back pain; and Whitsett Hill Entertainment, a company that develops,
produces major motion pictures.
He has authored and co-authored three books and several articles,
which served as the foundation for promoting his businesses.
His books, Quality on Trial, and Customer Relationship
Management, were best sellers among business books and
have been translated and published in several languages.
Dr. Howe is actively involved in a not for profit organization
Boundary Waters Experience, an organization dedicated
to providing young people with adventurous experiences in the
wilderness. He resides in San Diego, California with his wife,
Irene. He is the father of two sons, Ryan and Derek, and has
back to top
Maynard Howe brings a richly diverse background to Stemedica.
Along with his brother, Roger, he has launched five successful
ventures in the medical device, software, testing and measurement,
quality and consulting fields. Most recently, as Co-Chairman
and CEO of Reliant Technologies, he led a team of scientists,
engineers and physicians in developing, testing and launching
the revolutionary medical laser for skin surgery known as Fraxel.
The Fraxel is an award winning medical laser technology that
has resulted in defining a new category of science called fractional
photothermolysis. This new science involves the role of lasers
and the patients own stem cells in wound healing and dermatological
and plastic surgery. The Fraxel laser, in conjunction with autologous
and allogeneic stem cells is currently being used in new clinical
study to treat scars, burn scars and diabetic ulcers. Reliant
Technology has achieved a strong intellectual property position
with over 20 patents issued and 40 pending applications. In
addition, Reliant has secured 13 FDA clearances, and is well
on its way to becoming the market leader with distribution in
over 15 countries.
During his leadership tenure at Reliant, he lead the team responsible
for securing funding from individual and institutional investors
including: Three Arch Partners, Pinnacle Venture Partners, Meritech
Capital Partners, Delphi Ventures and Comerica Bank. Reliant
has recently filed an S1 with underwriter representation from
investment bankers Piper Jaffrey, Banc of America Securities,
Jeffries and Company and RBC Capital Markets.
Prior to Reliant helped more than fifty Fortune 500 companies
coordinate their company-wide quality and customer relationship
initiatives. As a senior executive and co-founder of a leading
customer and market research company, he was responsible for
conducting extensive marketing and branding campaigns, market
assessments and trend research in both business-to-business
and business-to-consumer environments. Maynard is also co-founder
and Chairman of BioPharma Scientific, a leading edge company
specializing in the integration of pharmaceutical nanotechnology
into the field of nutraceuticals. He has experience in setting
up distribution and managing sales channels throughout North
America, Europe and parts of Asia.
Maynard holds a Bachelor of Science Degree, Master of Science
Degree and a Doctorate in Psychology. His ability to recruit
world leaders and industry experts and create a culture of innovation
and teamwork has contributed to the successes achieved in the
businesses he has co-founded and those in which he has provided
services as a board member and consultant.
Dr. Howe is the author and co-author of numerous articles and
top selling business books. He is a nationally and internationally
recognized speaker and lecturer. His benchmark book on quality,
Quality on Trial, Bringing Customer Relationships
into Focus, is in its second edition and has been published
in several languages. Other books include a five part implementation
manual series, Business to Business Marketing Management
System, published by McGraw-Hill.
He is actively involved as a Board Member and Chairman of the
Advanced Development Committee for Alliant International University.
Dr. Howe continues to Chair Doctoral Dissertations in the Behavioral
back to top
Tankovich is a recognized innovator, researcher and educator for
laser applications in medicine, cancer vaccines, stem cell therapies
and other medical related disciplines. He is a proven researcher
and has inventions that have set the basis for entire new industries.
Founder and Director of several corporations, Dr. Tankovich is
respected worldwide and published and honored for his innovative
work in laser and new drug usage including medical and aesthetic
applications. He has more than 110 US and other foreign patents
issued and pending.
Dr. Tankovich has been an educator at international universities,
published more than 60 articles and has been a presenter or
speaker at over 200 conferences or seminars. He has conducted
extensive research and development of laser applications for
medical usage as well as for cancer research. Among his numerous
awards and honors is the Gold Kurchatov Medal for the Atomic
Science Application in Medicine and Biology awarded by the Atomic
Energy Agency in 1998. Dr. Tankovich's inventions include devices
for laser hair removal and laser skin peeling, non-ablative
wrinkle removal, and laser lancet (all three licensed and FDA
approved). He was the first in the world to propose, invent,
develop, patent, build and use a 1.54 micron Er:Glass laser
for medical applications. He is a scientific advisor to Reliant
Technology and is the pioneer of the science of Laser Sparing
Technology, the supporting intellectual property of the Fraxel
Laser and the genesis of what is now known as fractional photolysis.
Dr. Tankovich has conducted extensive research and development
of laser applications for medical usage, stem cell therapies,
and cancer research. As a result of his advanced technology
laser applications in plastic and cosmetic surgery and dermatology,
ThermoLase Corporation was founded and still uses his intellectual
property and patents on laser hair removal and skin resurfacing.
Dr. Tankovich also has worked on laser diagnosis and surgery
of malignant and background diseases of uterine cervix and the
intraoperation laser diagnosis of early forms of breast cancer.
He holds an MD degree from Semashco Medical University (Moscow),
a Master of Science degree in Plasma Physics from Moscow University,
and a PhD in BioPhysics from Lomonosov Moscow University.
back to top
Kharazi is a physician by training. He finished Medical School
in 1978 in Kiev, Ukraine, where he earned his MD degree in internal
medicine and pathology. From 1978 to 1981 he was a postdoctoral
fellow at the Kiev Institute of Gerontology. Dr. Kharazi received
extensive training in cell biology and immunology, including tissue
culture and subsequently earned his PhD in immunology. He studied
age-related pathological changes of the immune system in mice
and humans and his research interests included the possibility
of restoring immunity in aged mice using stem cells from young
adult mice. Dr. Kharazi was one of the first to discover the inhibitory
effects of old thymus in mice and later published on this subject.
In 1989 Alex was invited to work as a research fellow in the
department of Pathology at the Tokyo Metropolitan Institute
of Gerontology in Japan. There he studied early progenitors
for adult thymic epithelial cells and successfully established
adult thymic epithelial cell lines. He received extensive training
in immuno-cytology and flow cytometry.
In 1991 Dr. Kharazi was invited to UCLA to serve as Chief Pathologist
of an EPA-controlled study on the effects of magnetic fields
on the incidence of lymphoma in mice. While at UCLA he received
extensive training in U.S. Good Laboratory Practices and regulatory
affairs. The results of the study were reported to the United
States Congress. From 1998 through 2006 Dr. Kharazi served as
Chief Scientist of the Immunotherapy laboratory at St. Vincent
Medical Center in Los Angeles, California. There, his research
interests focused on cancer treatment using tumor vaccines,
which were designed and manufactured to activate a patient’s
own immune system. He successfully designed, prepared, and patented
a breast cancer vaccine using genetic engineering. He also conducted
scientific work on the role that dendritic cells play in the
generation of anti-tumor immune response. Dr. Kharazi has hands-on
experience in conducting FDA approved clinical trials.
Dr. Kharazi has published over 30 research articles in scientific
journals and has contributed to several chapters in scholarly
books. He has presented his data at numerous national and international
scientific meetings. He is an active member of many distinguished
societies such as The American Association for Cancer Research.
In addition, he served as a consultant to several research companies
and he has also been a faculty member at the University of Southern
California in Los Angeles.
back to top
Dr. Baranov is an internationally recognized leading researcher,
innovator and educator for applications of physical chemistry,
biophysical methods and imaging technology in cancer research
and biotech related disciplines. He has published more than 60
articles (including publications in such highly-ranked scientific
journals as Cell, Cancer Cell, and Proceedings of National Academy
of Sciences of the USA). He has presented the results of his research
at over 30 conferences and seminars worldwide.
has been an educator at several international universities and
an inventor of three U.S. patents. He was also a consultant
for several U.S. companies specializing in nutrition, cosmetics
and cancer research. Dr. Baranov's research has been significant
in the anthracycline drugs' cell membrane transport kinetics
and their interaction with DNA; the development of vital fluorescent
dye and laser based technology for the early cancer diagnosis
for clinical usage; the implementation of a double derivative
method for data image analysis of collagen structure in normal
and pathological tissues (breast cancer and diabetes); the application
of fluorescent, polarized, and nanosecond time-resolved spectroscopy
for studies of drug interactions and their molecular complexes
with their targets.
back to top
is currently the VP of Operations of Stemedica. He has particular
expertise in working with start up organizations. During his tenure
he served as Chief Operating Officer and Chief Financial Officer
of four different start-up companies and built the financial,
personnel, and administrative infrastructure necessary for growth,
raising capital and expanding the company's resources with a variety
of financing mechanisms. Derek has completed several mergers and
acquisitions. He has worked as COO/CFO in the medical, technology,
nutritional, and entertainment industries.
Derek serves as the Founder and Executive Chairman of CornerStone
Ministries as well as a Board member for BioPharma Scientific.
He has played an integral role in the development of numerous
growth oriented companies and has provided strategic and tactical
consulting to many established organizations. Derek received
his B.S. in Business Administration with an emphasis in Accounting
and Finance from Northwestern College. He graduated Summa Cum
back to top
Brotman, PhD, JD is Vice President of Intellectual Property.
Dr. Brotman develops intellectual property strategies to implement
and execute the Company's business plans. In industry and academia,
he has broad strategic experience in biotech, therapeutics and
diagnostic patent preparation, prosecution, and licensing for
monetizing intellectual property value.
He earned a PhD in genetics from The University of California
Davis, and joined the faculty of Cornell University as assistant
professor of genetics. Dr. Brotman, as a free-lance journalist,
reported for the New York Times Magazine, the Los Angeles Times,
and Chicago Tribune on new technologies in human reproduction.
He received a law degree from Southwestern University in Los
Angeles in 1989, and practiced patent law at partner level in
major San Diego law firms prior to joining Stemedica in 2006.
back to top
McGuigan brings thirty years of marketing, branding and marketplace
development experience to Stemedica. Dave’s marketing leadership
has helped launch innovative marketing and public relations initiatives
for such organizations as the NHL Detroit Red Wings, (IMG) International
Management Group, Marketing Resources, USAA Insurance, Project
Concern International and Children’s Hospital of San Diego.
Dave has extensive experience in the delivery of these high
profile marketing and public relations campaigns through multiple
distribution channels including motion picture, television,
internet and print media. Dave sits on the Board of several
for-profit and non-profit organizations, and brings a wealth
of organizational and strategic expertise to Stemedica.
back to top
Howe is the owner and Medical Director of the San Diego Clinic
of Preventive Medicine, which is a private medical clinic specializing
in the most current treatments in alternative, as well as mainstream
medicine. As both a medical physician, and a chiropractor, Dr.
Howe has had extensive training in clinical nutrition throughout
his thirty years in the medical field, and incorporates this
natural approach to health
Dr. Howe is a member of the American College for Advancement
in Medicine, and a member of the American College of Osteopathic
Pain Managements and Sclerotherapy
back to top
Vitums was the Manager of Financial Reporting at Nanogen, Inc.,
a publicly-traded NASDAQ biotech company, where he was responsible
for managing internal and external financial reporting. During
his time at Nanogen, he was responsible for implementing a worldwide
financial reporting and budgeting system, helped the Company
raise approximately $60 million in equity and royalty financing
and integrated the financial reporting and budgeting of the
four entities Nanogen acquired during this period. From May
2000 to December 2005, Mr. Vitums worked at Cytori Therapeutics,
a publicly traded NASDAQ regenerative-cell (stem cell) company,
holding various positions, most recently as the Controller.
He was also responsible for managing the internal and external
financial reporting at the company and was a leader in the team
that took the company public on the Frankfurt Stock Exchange
in Germany in August of 2000. Prior to Cytori Therapeutics,
Mr. Vitums worked at various public accounting firms including
PriceWaterhouseCoopers. Mr. Vitums graduated Cum Laude, with
a Bachelors degree from Wayne State University in Detroit, Michigan
and is a Certified Public Accountant.
back to top
Lukashev brings 20 years experience in advanced research and development
in solid state and eximer lasers, nonlinear optics and interaction
of laser radiation with matter. Dr. Lukashev currently works with
a laser for hydrogen bond modification which was invented while
he was working at Moscow’s General Physics Institute with Nobel
Prize Winner and Academician A. Prokhorov. Dr. Lukashev has a
long track record of new product development for the medical and
semiconductor industries including lasers for hair removal, vascular
treatment and skin resurfacing. He has also participated in the
development of optical methods of non-invasive cancer diagnostics
and was the managing director of development and manufacturing
of DermaChiller 4, an FDA-approved hand-held device for cooling
the skin during laser and medical procedures.
Dr. Lukashev currently holds 7 US patents and has been published
in 36 peer review journals and conference proceedings.
back to top